688506 百利天恒
已收盘 12-15 15:00:00
资讯
新帖
简况
四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局
华夏时报 · 12-10
四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
每日经济新闻 · 12-01
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
美股速递 · 11-30
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议
美股速递 · 11-30
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
智通财经 · 11-30
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
百利天恒（688506）披露召开2025年第三季度业绩说明会公告，11月27日股价下跌0.85%
证券之星 · 11-27
百利天恒（688506）披露召开2025年第三季度业绩说明会公告，11月27日股价下跌0.85%
百利天恒：截至2025年9月30日，股东户数为5979户
证券日报 · 11-25
百利天恒：截至2025年9月30日，股东户数为5979户
四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议
美股速递 · 11-19
四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议
百利天恒(688506.SH)：iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点
智通财经 · 11-18
百利天恒(688506.SH)：iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点
每周股票复盘：百利天恒（688506）H股上市延迟
证券之星 · 11-16
每周股票复盘：百利天恒（688506）H股上市延迟
百利天恒IPO延迟！“A+H”还要等多久？
投资时报 · 11-14
百利天恒IPO延迟！“A+H”还要等多久？
688506，港股IPO延迟！
中国基金报 · 11-13
688506，港股IPO延迟！
百利天恒（688506）披露关于发行H股并上市的进展公告，11月12日股价上涨2.49%
证券之星 · 11-12
百利天恒（688506）披露关于发行H股并上市的进展公告，11月12日股价上涨2.49%
百利天恒宣布因市场状况决定推迟香港上市
美股速递 · 11-12
百利天恒宣布因市场状况决定推迟香港上市
罕见！百利天恒（2615.HK）招股截止前突然延迟上市 为什么？
新浪港股 · 11-12
罕见！百利天恒（2615.HK）招股截止前突然延迟上市 为什么？
【新股IPO】百利天恒(02615)决定全球发售将会延迟
金吾财讯 · 11-12
【新股IPO】百利天恒(02615)决定全球发售将会延迟
百利天恒决定推迟全球发行，未能按招股说明书推进
美股速递 · 11-12
百利天恒决定推迟全球发行，未能按招股说明书推进
超200亿美元重磅炸弹独步全球，百利天恒(02615)港股“C位出道”
智通财经 · 11-11
超200亿美元重磅炸弹独步全球，百利天恒(02615)港股“C位出道”
百利天恒(02615)11月7日至11月12日招股 预计11月17日上市
智通财经 · 11-07
百利天恒(02615)11月7日至11月12日招股 预计11月17日上市
【机构调研记录】蜂巢基金调研百利天恒
证券之星 · 11-06
【机构调研记录】蜂巢基金调研百利天恒
暂无数据
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":350.47,"timestamp":1765782000000,"preClose":359.93,"halted":0,"volume":971288,"delay":0,"changeRate":-0.0263,"floatShares":103000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":-9.46,"latestTime":"12-15 15:00:00","open":359.54,"high":362.98,"low":348.36,"amount":344000000,"amplitude":0.0406,"askPrice":350.47,"askSize":10,"bidPrice":350.08,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":359.93,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":395.92,"lowLimit":323.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":20.18,"roa":"--","roe":"--","epsLYR":9.25,"committee":0.235294,"marketValue":144700000000,"turnoverRate":0.0094,"status":1,"afterMarket":{"amount":0,"volume":0,"close":350.47,"buyVolume":0,"sellVolume":0,"time":1765784037768,"indexStatus":"已收盘 12-15 15:30:00","preClose":359.93},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1765785600000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":36060000000},"requestUrl":"/m/hq/s/688506/tweets","defaultTab":"tweets","newsList":[{"id":"2590448581","title":"四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590448581","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590448581?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:50","pubTimestamp":1765367400,"startTime":"0","endTime":"0","summary":"华夏时报记者 王瑜 于娜 北京报道随着百利天恒(688506.SH）市值从百亿元跃升为千亿元，公司创始人、董事长朱义一举问鼎四川首富。这位自称“打麻将都要All in”的狠人，在创新药赛道上更是 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688506","159992","BK0239"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"｜2025年12月1日星期一｜NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告，子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BK1574","159938","09939","91194","BK1161","688062","688506","BK1515","BK0239"],"gpt_icon":0},{"id":"1197403315","title":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1197403315","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197403315?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","BK0239","LU0096364046.USD","LU1868837136.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU2125154935.USD","LU0225771236.USD","LU1093756325.SGD","LU2125154778.USD","LU0321505868.SGD","BK4007","LU2242646821.SGD","LU1291159041.SGD","BK4585","IE00BFXG1179.USD","688506","IE00BJT1NW94.SGD","LU1718418525.SGD","LU1430594728.SGD","LU0237698245.USD","LU0267386448.USD","IE00BSNM7G36.USD","LU1670710588.SGD","LU0456855351.SGD","BK4588","LU1585245621.USD","BK4532","IE00B2B36J28.USD","LU0114720955.EUR","LU0882574055.USD","LU1868836591.USD","LU1323610961.USD","BK4559","LU0868494617.USD","LU0061475181.USD","LU1868837300.USD","BMY","BK4534","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU1670710661.SGD","LU1032466523.USD","LU2242652126.USD","LU0306807586.USD","LU1074936037.SGD","LU1670711040.USD","LU1670711123.USD","IE0002141913.USD","LU2133065610.SGD","LU1261432733.SGD","LU2360032135.SGD","LU1868836914.USD","LU1093756168.USD","LU1571399168.USD","LU1989771016.USD","LU1868836757.USD","BK4581","LU0225284248.USD"],"gpt_icon":0},{"id":"1112180261","title":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112180261","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112180261?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元的里程碑付款，涉及Iza-Bren全球战略协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU1430594728.SGD","LU2125154778.USD","LU0306806265.USD","LU1585245621.USD","BK4559","LU0321505868.SGD","BK0239","BK4007","IE00BJT1NW94.SGD","BK4588","LU1868836914.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","IE0009355771.USD","LU0267386448.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU1093756168.USD","LU0306807586.USD","LU1074936037.SGD","BK4534","LU1868837136.USD","LU1093756325.SGD","LU2125154935.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU1868836757.USD","BK4532","LU0061475181.USD","LU1032466523.USD","LU0985481810.HKD","LU2242646821.SGD","IE00BSNM7G36.USD","BMY","IE0002141913.USD","LU1868836591.USD","LU1989771016.USD","LU1261432733.SGD","BK4585","688506","LU1718418525.SGD","LU2133065610.SGD","LU1571399168.USD","LU0321505439.SGD","LU1670710661.SGD","LU1670711040.USD","LU1670711123.USD","LU0237698245.USD","LU1670710588.SGD","LU0096364046.USD","BK4581","LU0868494617.USD","LU2360032135.SGD","LU0114720955.EUR","LU0882574055.USD","LU1291159041.SGD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2587799680","title":"百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2587799680","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587799680?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:56","pubTimestamp":1764492983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司全资子公司SystImmune近期收到由BMS支付的2.5亿美元里程碑付款。根据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0096364046.USD","BK4585","LU1868836757.USD","IE00BJT1NW94.SGD","688506","BMY","LU0868494617.USD","IE00BSNM7G36.USD","LU1430594728.SGD","LU0225771236.USD","LU0267386448.USD","BK4588","LU1093756168.USD","LU2242646821.SGD","LU0306806265.USD","LU1032466523.USD","LU1585245621.USD","LU1291159041.SGD","LU2133065610.SGD","91194","LU0306807586.USD","BK4532","LU0114720955.EUR","LU1074936037.SGD","LU1868837300.USD","LU1868837136.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU2242652126.USD","LU1670711123.USD","LU1718418525.SGD","LU2125154935.USD","LU1670710588.SGD","BK4559","LU2360032135.SGD","BK0239","BK4007","LU1670710661.SGD","02615","LU0882574055.USD","IE00B2B36J28.USD","LU0985481810.HKD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1868836914.USD","LU1261432733.SGD","IE0002141913.USD","LU1868836591.USD","BK4581"],"gpt_icon":0},{"id":"2586722547","title":"百利天恒（688506）披露召开2025年第三季度业绩说明会公告，11月27日股价下跌0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586722547","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586722547?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:32","pubTimestamp":1764253945,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，百利天恒报收于384.99元，较前一交易日下跌0.85%，最新总市值为1589.52亿元。公司近日发布公告称，四川百利天恒药业股份有限公司将于2025年12月4日15:00-16:00通过上证路演中心以网络文字互动方式召开2025年第三季度业绩说明会，介绍公司经营成果、财务状况及发展战略。投资者可于2025年11月28日至12月3日16:00前通过上证路演中心预提问栏目或公司邮箱ir@baili-pharm.com提交问题。说明会结束后可通过上证路演中心查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","BK0239"],"gpt_icon":1},{"id":"2586475897","title":"百利天恒：截至2025年9月30日，股东户数为5979户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475897","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586475897?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:07","pubTimestamp":1764076026,"startTime":"0","endTime":"0","summary":"证券日报网讯百利天恒11月25日在互动平台回答投资者提问时表示，截至2025年9月30日，股东户数为5，979户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574450719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","02615","688506"],"gpt_icon":0},{"id":"1122300755","title":"四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1122300755","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122300755?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:02","pubTimestamp":1763550123,"startTime":"0","endTime":"0","summary":"四川百利天恒表示，与中国银行四川省分行签署了不少于80亿元的信贷协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2584605809","title":"百利天恒(688506.SH)：iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584605809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584605809?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:23","pubTimestamp":1763425416,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的全球首创、新概念且唯一进入III期临床阶段的EGFR×HER3双抗ADC在食管鳞癌的III期临床试验中，经独立数据监查委员会判断，在预设的期中分析中达到无进展生存期和总生存期双主要终点，适应症为：既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。这是全球首个ADC药物在食管癌治疗中取得PFS/OS双阳性结果的III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","91194","02615","688506","BK4134","BK0239"],"gpt_icon":0},{"id":"2583654377","title":"每周股票复盘：百利天恒（688506）H股上市延迟","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654377?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:30","pubTimestamp":1763238628,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，百利天恒报收于371.62元，较上周的349.93元上涨6.2%。本周，百利天恒11月14日盘中最高价报378.0元。本周关注点公司公告汇总：百利天恒因市场情况延迟H股全球发售及上市。公司公告汇总四川百利天恒药业股份有限公司正在推进发行H股并在香港联合交易所主板上市的工作。2025年11月7日，公司已在香港联交所网站刊登H股招股说明书及相关发售安排。公告不构成对任何个人或实体认购H股的要约或要约邀请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"2583522901","title":"百利天恒IPO延迟！“A+H”还要等多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583522901","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583522901?lang=zh_cn&edition=full","pubTime":"2025-11-14 14:54","pubTimestamp":1763103240,"startTime":"0","endTime":"0","summary":"编者按：拆解企业招股、估值、上市表现，以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划，深度探寻每一次资本浪潮背后的机遇与逻辑，敬请关注。投资时间 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251114/c672484389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2583028534","title":"688506，港股IPO延迟！","url":"https://stock-news.laohu8.com/highlight/detail?id=2583028534","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583028534?lang=zh_cn&edition=full","pubTime":"2025-11-13 12:39","pubTimestamp":1763008740,"startTime":"0","endTime":"0","summary":"【导读】百利天恒港股IPO再遇波折，决定延迟H股全球发售及上市11月12日晚间，百利天恒发布公告称，鉴于目前市场情况，公司决定延迟H股全球发售及上市。百利天恒2024年6月21日官宣拟在港股上 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251113/c672453895.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251113/c672453895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2582667377","title":"百利天恒（688506）披露关于发行H股并上市的进展公告，11月12日股价上涨2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582667377","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582667377?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:21","pubTimestamp":1762957282,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，百利天恒报收于360.85元，较前一交易日上涨2.49%，最新总市值为1489.86亿元。该股当日开盘348.0元，最高369.86元，最低348.0元，成交额达4.38亿元，换手率为1.18%。公司近日发布公告称，四川百利天恒药业股份有限公司正在推进发行H股并在香港联合交易所主板上市的工作。鉴于当前市场情况，公司决定延迟本次H股的全球发售及上市，并于2025年11月12日在香港联交所网站发布相关公告。公告不构成对任何个人或实体认购H股的要约或要约邀请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"gpt_icon":0},{"id":"1192401786","title":"百利天恒宣布因市场状况决定推迟香港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1192401786","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192401786?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:22","pubTimestamp":1762939330,"startTime":"0","endTime":"0","summary":"百利天恒宣布因市场状况决定推迟香港上市","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2582329682","title":"罕见！百利天恒（2615.HK）招股截止前突然延迟上市 为什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582329682","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582329682?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:07","pubTimestamp":1762938420,"startTime":"0","endTime":"0","summary":" 今年以来持续火热的港股IPO市场突现异常案例，已在A股上市的药企百利天恒 ，在港股招股期即将结束时突然宣布延迟H股上市。 百利天恒H股已于11月7日至12日中午招股，发行863.4万股H股，一成于香港作公开发售，发售价347.5港元至389港元，集资最多33.6亿港元，每手100股，一手入场费39292.3港元。 市场质疑百利天恒以“现行市况”为由引依据是否充分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-11-12/doc-infxcura4847567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2582343793","title":"【新股IPO】百利天恒(02615)决定全球发售将会延迟","url":"https://stock-news.laohu8.com/highlight/detail?id=2582343793","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582343793?lang=zh_cn&edition=full","pubTime":"2025-11-12 12:14","pubTimestamp":1762920884,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百利天恒(02615)公告公布，股份原订于2025年11月17日(星期一)上午九时正于联交所开始买卖。鉴于现行市况，经征询整体协调人后，公司已决定全球发售将会延迟，且将不会根据招股章程进行。因此，有关国际发售的国际包销协议将不会订立，因此有关香港公开发售的香港包销协议将不会成为无条件。延迟全球发售的决定并无影响公司的目前业务，且公司致力发展及扩充业务。同时，公司及其整体协调人正在审慎评估有关全球发售及上市的更新时间表。","market":"fut","thumbnail":"https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"1186082163","title":"百利天恒决定推迟全球发行，未能按招股说明书推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1186082163","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186082163?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:19","pubTimestamp":1762917550,"startTime":"0","endTime":"0","summary":"百利天恒决定推迟全球发行，未能按招股说明书推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2582638208","title":"超200亿美元重磅炸弹独步全球，百利天恒(02615)港股“C位出道”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582638208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582638208?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:54","pubTimestamp":1762822480,"startTime":"0","endTime":"0","summary":"11月7日，百利天恒发布公告宣布启动H股全球公开发售，并计划于香港联交所主板上市。智通财经APP了解到，百利天恒本次全球发售H股基础发行股数为8,634,300股。也就是说，百利天恒有望在H股上市当日即纳入港股通。目前，百利天恒已率先跻身全球ADC创新药第一阵营，并释放出向全球MNC转化的强烈信号。“下一代基石癌症疗法”带来的投资确定性此次百利天恒港股IPO引入了三家重磅基石投资者。该公司由此成为百利天恒重要的战略股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2581041178","title":"百利天恒(02615)11月7日至11月12日招股 预计11月17日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2581041178","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581041178?lang=zh_cn&edition=full","pubTime":"2025-11-07 06:50","pubTimestamp":1762469428,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 于2025年11月7日至11月12日招股，该公司拟全球发售863.43万股，其中香港发售占10%，国际发售占90%，另有15%超额配股权，每股发售价347.5-389港元。每手100股，预期股份将于2025年11月17日在联交所开始买卖。约60.0%将用于拨付公司于中国内地以外地区的生物候选药物的研发活动。约30.0%将用于建立公司的全球供应链，主要为公司在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02615","BK0239","688506"],"gpt_icon":0},{"id":"2581081579","title":"【机构调研记录】蜂巢基金调研百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081579?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:05","pubTimestamp":1762387556,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月5日披露的机构调研信息，蜂巢基金近期对1家上市公司进行了调研，相关名单如下：1）百利天恒 调研纪要：iza-bren和T-Bren共5项研究成果入选2025 ESMO，覆盖鼻咽癌、肺癌、卵巢癌、乳腺癌及胃癌，展现良好有效性和安全性。旗下最近一年表现最佳的公募基金产品为蜂巢先进制造混合发起式A，最新单位净值为1.29，近一年增长33.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600004984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","688506"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765800942553,"stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0025},{"period":"3month","weight":0.029},{"period":"6month","weight":0.1058},{"period":"1year","weight":0.711},{"period":"ytd","weight":0.8773}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"17208股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}